Siirry sisältöön

Biovian showcasing expertise at the Oncolytic Virotherapy Summit in Boston

We are thrilled to announce that Biovian will be exhibiting at the upcoming Oncolytic Virotherapy Summit, scheduled to take place from December 12-14 in the vibrant city of Boston, MA.

As part of this summit, we are excited to share that our very own Magnus Gustafsson will deliver a compelling talk on “Adenovirus Process Development and Clinical Trial Manufacture.” This insightful presentation is scheduled for December 14 at 1:00 PM (EST).

Biovian has been at the forefront of biopharmaceutical development, specializing in providing state-of-the-art services for the production and development of viral vector-based therapies. Our participation in the Oncolytic Virotherapy Summit underscores our commitment to advancing the field and collaborating with companies developing innovative therapies to help patients in need.

We invite you to connect with our experts, Jayme Tortorici and Magnus Gustafsson, at the summit to discuss our latest advancements, capabilities, and how Biovian can contribute to the success of your virotherapy programs.

We look forward to connecting with you at the Oncolytic Virotherapy Summit in Boston!

About Oncolytic Virotherapy Summit

The Oncolytic Virotherapy Summit brings together experts and professionals in the field of oncolytic virotherapy. The summit serves as a platform for sharing cutting-edge research, discussing advancements in the field, and fostering collaboration among industry leaders. Attendees have the opportunity to participate in presentations, panel discussions, and networking sessions, gaining insights into the latest trends and discoveries in oncolytic virotherapy.

The summit fosters three days of carefully curated sessions, gathering 100+ OV trailblazers across sessions spanning Early Discovery, Translation, Clinical Development, Chemistry, Manufacturing & Controls (CMC) and Regulations to overcome the industry’s largest and critical bottlenecks, such as:

  • Adopting effective & novel viral platforms & employing a critical selection of transgene
  • Revolutionizing the delivery of OV’s through employing next-generation IT carrier Cells
  • Ensuring improved CMC, GMP Manufacturing, and adherence to regulatory standards
  • Selecting combination therapies to guarantee OV candidates are streamlined through clinic

Explore more about the summit here: